Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of House Dust Mite SLIT in Perennial Allergic Rhinitis
NCT01014325Phase 3Unknown
- Sponsor
- ROXALL Medizin GmbH
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of House dust mite allergen extract in allergic rhinitis (AR), sponsored by ROXALL Medizin GmbH. Status: unknown.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01014325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01014325.